Karin Wisskirchen

1.1k total citations
24 papers, 504 citations indexed

About

Karin Wisskirchen is a scholar working on Oncology, Epidemiology and Immunology. According to data from OpenAlex, Karin Wisskirchen has authored 24 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 13 papers in Epidemiology and 9 papers in Immunology. Recurrent topics in Karin Wisskirchen's work include Hepatitis B Virus Studies (13 papers), CAR-T cell therapy research (10 papers) and Hepatitis C virus research (7 papers). Karin Wisskirchen is often cited by papers focused on Hepatitis B Virus Studies (13 papers), CAR-T cell therapy research (10 papers) and Hepatitis C virus research (7 papers). Karin Wisskirchen collaborates with scholars based in Germany, United Kingdom and United States. Karin Wisskirchen's co-authors include Ulrike Protzer, Theresa Asen, Jochen M. Wettengel, Ke Zhang, Romina Bester, Daniela Stadler, Wang‐Shick Ryu, Chunkyu Ko, Anindita Chakraborty and Jane A. McKeating and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Immunology and PLoS ONE.

In The Last Decade

Karin Wisskirchen

21 papers receiving 495 citations

Peers

Karin Wisskirchen

EPIDE

HEPAT

ONCOL

IMMUN

Jochen M. Wettengel Germany

Theresa Asen Germany

Klaus M. Breiner Germany

Daniela Stadler Germany

Clemens Jäger Germany

Janine Kah Germany

Kaitao Zhao China

А. А. Гражданцева Russia

Miriam Triyatni Switzerland

Chunkyu Ko Germany

Jochen M. Wettengel Germany

Karin Wisskirchen

360 ×1.2

EPIDE

233 ×1.2

HEPAT

69 ×0.4

ONCOL

62 ×0.5

IMMUN

126 ×1.1

Citations per year, relative to Karin Wisskirchen Karin Wisskirchen (= 1×) peers Jochen M. Wettengel

Countries citing papers authored by Karin Wisskirchen

Since Specialization

Citations

This map shows the geographic impact of Karin Wisskirchen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Wisskirchen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Wisskirchen more than expected).

Fields of papers citing papers by Karin Wisskirchen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Wisskirchen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Wisskirchen. The network helps show where Karin Wisskirchen may publish in the future.

Co-authorship network of co-authors of Karin Wisskirchen

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Wisskirchen. A scholar is included among the top collaborators of Karin Wisskirchen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Wisskirchen. Karin Wisskirchen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Wei, Karin Wisskirchen, Yuhong Zhou, et al.. (2025). Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial. Gut. 75(1). 147–160. 1 indexed citations

Du, Shunda, Hui‐Chuan Sun, Jinlin Hou, et al.. (2025). LBP-017 SCG101 HBV-specific TCR-T cell therapy demonstrates dual antiviral and antitumor activities, achieving HBV clearance in liver biopsies and functional cure in HBV-related hepatocellular carcinoma patients. Journal of Hepatology. 82. S77–S78. 1 indexed citations

Du, Shunda, Karin Wisskirchen, Ke Zhang, & Ulrike Protzer. (2024). Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”. Clinical and Molecular Hepatology. 31(1). e44–e47.

Wan, Xueshuai, Karin Wisskirchen, Xiaorui Wang, et al.. (2024). Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting. Clinical and Molecular Hepatology. 30(4). 735–755. 16 indexed citations

Wisskirchen, Karin, et al.. (2023). The role of tumor-necrosis receptor associated factor 1 (TRAF-1) and 5 (TRAF-5) in platelet activation. Atherosclerosis. 379. S37–S37.

Debeleç-Bütüner, Bilge, et al.. (2022). Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins. Frontiers in Immunology. 13. 1029214–1029214. 6 indexed citations

Du, Shunda, Yuhong Zhou, Xiujuan Qu, et al.. (2022). Antiviral and antitumor activity of SCG101, an autologous HBV-specific T cell receptor engineered T cell (TCR-T) therapy in HBV-related advanced hepatocellular carcinoma (HCC) patients after receiving ≥2 prior lines of systemic therapies. Journal of Hepatology. 77. S384–S384.

Zhao, Lili, Marc Ringelhan, Karin Wisskirchen, et al.. (2021). Hepatitis B virus envelope proteins can serve as therapeutic targets embedded in the host cell plasma membrane. Cellular Microbiology. 23(12). e13399–e13399. 6 indexed citations

Abdulhaqq, Shaheed, Abigail B. Ventura, Jason S. Reed, et al.. (2021). Identification and Characterization of Antigen-Specific CD8+ T Cells Using Surface-Trapped TNF-α and Single-Cell Sequencing. The Journal of Immunology. 207(12). 2913–2921. 2 indexed citations

10.

Kosinska, Anna D., et al.. (2021). Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B. Frontiers in Immunology. 12. 734246–734246. 18 indexed citations

11.

Schiemann, Matthias, K. Witter, Christina E. Zielinski, et al.. (2021). Characterization of a library of 20 HBV-specific MHC class II-restricted T cell receptors. Molecular Therapy — Methods & Clinical Development. 23. 476–489. 5 indexed citations

12.

Pinci, Francesca, et al.. (2021). Hepatitis-D Virus Infection Is Not Impaired by Innate Immunity but Increases Cytotoxic T-Cell Activity. Cells. 10(11). 3253–3253. 3 indexed citations

13.

Wisskirchen, Karin, Janine Kah, Antje Malo, et al.. (2019). T cell receptor grafting allows virological control of hepatitis B virus infection. Journal of Clinical Investigation. 129(7). 2932–2945. 59 indexed citations

14.

Festag, Julia, Simon P. Fräßle, Theresa Asen, et al.. (2019). Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model. Molecular Therapy. 27(5). 947–959. 41 indexed citations

15.

Ko, Chunkyu, Anindita Chakraborty, Jochen M. Wettengel, et al.. (2018). Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. Journal of Hepatology. 69(6). 1231–1241. 164 indexed citations

16.

Wisskirchen, Karin, Janine Kah, Aurelio F. Malo, et al.. (2018). T cells grafted with HBV-specific T-cell receptors of high functional avidity achieve functional cure of HBV infection in humanized mice. Journal of Hepatology. 68. S19–S19. 2 indexed citations

17.

Wisskirchen, Karin, Regina Feederle, Hinrich Abken, et al.. (2018). GPR64-specific CAR-transgenic T cells selectively kill Ewing sarcoma in vivo. Kölner Universitäts PublikationsServer (Universität zu Köln). 1 indexed citations

18.

Wisskirchen, Karin, Theresa Asen, Luise Weigand, et al.. (2017). Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use. PLoS ONE. 12(8). e0182936–e0182936. 28 indexed citations

19.

Sautto, Giuseppe A., Karin Wisskirchen, Nicola Clementi, et al.. (2015). Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut. 65(3). 512–523. 71 indexed citations

20.

Wisskirchen, Karin, Julie Lucifora, Thomas Michler, & Ulrike Protzer. (2014). New pharmacological strategies to fight enveloped viruses. Trends in Pharmacological Sciences. 35(9). 470–478. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact